About: Abnormal liver function tests in COVID‐19 patients: relevance and potential pathogenesis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Abnormal liver function tests in COVID‐19 patients: relevance and potential pathogenesis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Abnormal liver function tests in COVID‐19 patients: relevance and potential pathogenesis
Creator	Farinati, Fabio Fantin, Alberto Bertolini, Anna Bodewes, Frank Fiorotto, Romina »more»
source	Medline; PMC
abstract	Abnormal liver function tests (LFTs) are reported frequently in hospitalized coronavirus disease 2019 (COVID‐19) patients. A review of the literature shows that 46% of admitted COVID‐19 patients had elevated plasma aspartate aminotransferase (AST) and 35% had elevated alanine aminotransferase (ALT) levels on admission. Elevations of both AST and ALT are mostly below 5 times the upper reference limit and are associated with severe disease and increased inflammatory markers. AST and ALT elevations are more frequent in US patients compared to Chinese patients. Mild elevations in gamma‐glutamyltransferase (GGT), alkaline phosphatase (ALP) and total bilirubin are also reported, although less frequently. Significant impairment of liver function or overt liver failure as the cause of death in COVID‐19 rarely occur. There is no direct evidence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) hepatic infection, although a subset of hepatocytes and cholangiocytes express the host receptor utilized for cellular entry by SARS‐CoV‐2. The presence of pre‐existing liver disease in patients with elevated LFTs on admission has not been comprehensively assessed in most studies but is unlikely to account for all abnormalities in LFTs. Although abnormal LFTs are already frequently present upon admission before the start of treatment, drug‐induced liver injury should be taken into consideration, especially after the use of acetaminophen, lopinavir/ritonavir and remdesivir, which are potentially hepatotoxic. In conclusion, these initial observations suggest that the prevalence of abnormal LFTs is high in COVID‐19 patients, but that the clinical relevance is limited and that treatment is not required. The mechanisms underlying abnormal LFTs in COVID‐19 are likely multifactorial and related to a hyper‐inflammatory status and thrombotic microangiopathy that are observed in severe COVID‐19 disease.
has issue date	2020-07-23(xsd:dateTime)
bibo:doi	10.1002/hep.31480
bibo:pmid	32702162
has license	no-cc
sha1sum (hex)	79d902d79dabf4958a91968873ff692295acaaf1
schema:url	https://doi.org/10.1002/hep.31480
resource representing a document's title	Abnormal liver function tests in COVID‐19 patients: relevance and potential pathogenesis
has PubMed Central identifier	PMC7404414
has PubMed identifier	32702162
schema:publication	Hepatology
resource representing a document's body	covid:79d902d79dabf4958a91968873ff692295acaaf1#body_text
is schema:about of	named entity 'hospitalized' named entity 'levels' named entity 'patients' named entity 'reference limit' named entity 'frequently' »more»

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software